NIEHS and the U.S. Food and Drug Administration (FDA) convened the Consortium Linking Academic and Regulatory Insights on BPA Toxicity (CLARITY-BPA) to study the range of potential health effects from exposure to bisphenol A (BPA) in rats and provide data that can be used for regulatory decisions.
CLARITY-BPA united standard research practices used by regulators, called federal guideline studies, with innovative research conducted at universities through grants from NIEHS. One purpose of CLARITY-BPA was to assess whether these federal guideline studies are sensitive enough to detect health effects from low-dose, endocrine-disrupting chemicals.
CLARITY-BPA has two complementary components:
NTP released for public comment a draft report of the core study on February 23, 2018. It was reviewed by a panel of external scientific experts at NIEHS on April 26, 2018, which agreed with NTP conclusions that there were minimal toxic effects of BPA exposure in rats for the range of doses studied in the core report. The panel, however, recommended revisions to several specific interpretations of the study findings, which were considered by NTP and FDA staff when they finalized the core study report.
A final integrated report from this collaboration between NIEHS, NTP, FDA, and academic researchers is expected in 2019.